AstraZeneca is a global science-led biopharmaceutical company that focuses on the discovery development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put s... AstraZeneca is a global science-led biopharmaceutical company that focuses on the discovery development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive open and collaborative. This approach runs through all that we do. We focus on three main therapy areas Oncology Cardiovascular & Metabolic Disease CVMD and Respiratory and we are also selectively active in the areas of autoimmunity neuroscience and infection. Show more
AZN LAWSUIT ALERT: The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline PR Newswire NEW YORK, Jan. 30, 2025 NEW YORK, Jan. 30, 2025 /PRNewswire/...
Based on DESTINY-Breast06 Phase III trial results which showed ENHERTU demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year Approval brings...
Shareholders of AstraZeneca PLC Should Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZN PR Newswire NEW YORK, Jan. 27, 2025 NEW YORK, Jan. 27, 2025 /PRNewswire/...
AstraZeneca PLC Sued for Securities Law Violations - Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZN PR Newswire NEW YORK, Jan. 23, 2025 NEW YORK, Jan. 23, 2025...
AstraZeneca PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AZN PR Newswire LOS ANGELES, Jan. 23, 2025 LOS ANGELES, Jan. 23, 2025 /PRNewswire/ -- The...
The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZN PR Newswire NEW YORK, Jan. 20, 2025 NEW YORK , Jan. 20, 2025 /PRNewswire/ -- The Gross...
First approval in the US for AstraZeneca and Daiichi Sankyo’s DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death vs. chemotherapy...
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone First and only BTK inhibitor approved for the 1st-line...
Shareholders that lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class Action - AZN PR Newswire NEW YORK, Jan. 16, 2025 NEW YORK, Jan. 16, 2025 /PRNewswire/...
Application based on TROPION-Lung05 trial and supported by data from TROPION-Lung01 and TROPION-PanTumor01 trials Approval would mark the first for AstraZeneca and Daiichi Sankyo’s datopotamab...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
Symbole | Prix | Vol. |
---|---|---|
TCTMTCTM Kids IT Education Inc | US$ 0,764 (321,87%) | 729,72M |
NVDANVIDIA Corporation | US$ 120,07 (-3,67%) | 388,54M |
RIMEAlgorhythm Holdings Inc | US$ 0,02565 (5,12%) | 338,75M |
BHATBlue Hat Interactive Entertainment Technology | US$ 0,0355 (-11,25%) | 236,29M |
CLEUChina Liberal Education Holdings Ltd | US$ 0,1938 (30,77%) | 234,8M |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales